Aspire Biopharma
ASBP
2 hedge funds and large institutions have $5.36M invested in Aspire Biopharma in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
3,479% more capital invested
Capital invested by funds: $150K → $5.36M (+$5.21M)
0% more funds holding
Funds holding: 2 → 2 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$98.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Robinson Capital Management
Grosse Pointe Farms,
Michigan
|
-$55.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HCI
1
Harraden Circle Investments
New York
| $5.17M | +$5.3M | +375 | New |
|
|
CS
2
Clear Street
New York
| $183K | +$98.9K | +7 | +117% |
|
3
UBS Group
Zurich,
Switzerland
| $513 | – | – | – |
|
|
RCM
4
Robinson Capital Management
Grosse Pointe Farms,
Michigan
| – | -$55.7K | -4 | Closed |
|
ASBP Hedge Fund Activity: Q4 2024 in Review
2 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma (ASBP) for Q4 2024, worth a combined $5.36M — up 3,479% from $150K a quarter earlier.
Fund positioning in ASBP was balanced in Q4 2024: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Clear Street, adding an estimated $98.9K. The largest seller was Robinson Capital Management, exiting entirely with an estimated $55.7K sold.
- 2 institutional investors held Aspire Biopharma (ASBP) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $5.36M of Aspire Biopharma stock for Q4 2024, up 3,479% quarter-over-quarter.
- 1 fund opened new Aspire Biopharma positions in Q4 2024 and 1 closed out, a net change of 0 holders.
- The largest Aspire Biopharma buyer in Q4 2024 was Clear Street, an estimated $98.9K added.
- The largest Aspire Biopharma seller in Q4 2024 was Robinson Capital Management, an estimated $55.7K sold.
Based on aggregated 13F filings for Q4 2024.